Since an NMA consists of direct and indirect comparisons, it is difficult to draw definitive final conclusions from these results; however, they support the possibility that lorlatinib may be one of emerging first-line treatment options for ALK-p and ALK inhibitor-naïve advanced NSCLC. This evidence concerns the gene ALK and non-small cell lung carcinoma.